In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Carl D. Regillo, MD, discusses the impact of supplemental aflibercept on eyes with wet age-related macular degeneration treated with EYP-1901.
According to Regillo, a subgroup analysis of the phase 2 DAVIO 2 trial looked at the effect of supplemental injections after treatment with EYP-1901 (EyePoint Pharmaceuticals) on vision and anatomic outcomes.
“What we did is we compared eyes without supplements to the entire patient population in the EYP arms and did not see a difference, both in BCVA outcomes or